



MEDICAL TIPS

OMEPREN-D Capsules

Issue IV, No.15, 2023

A real-world retrospective study of Omeprazole-Domperidone combination in managing acid peptic disease with proton-pump inhibitors in patients with type 2 diabetes mellitus (PRIDE-2)

Saboo B et al., Drugs Context. 2023; 12: 2022-10-3.

- Type 2 diabetes mellitus (T2DM) has been recognized as a risk factor for complicated acid peptic disease (APD).
- Proton pump inhibitors (PPIs) and Domperidone are frequently used to treat the symptoms of APD; consequently, the current study assessed their efficacy in treating APD in individuals with T2DM.
- Significant proportion of patients reported alleviation from APD symptoms, like abdominal pain (91.6%), epigastric burning, (68.7%), nausea (89.5%), altered bowel movements (94.7%), flatulence (100%) and loss of appetite (93.6%) with Omperazole-Dompridone.
- Omperazole-Dompridone showed no significant side effects, demonstrating its safety when used along with oral hypoglycemic agents (OHAs).

Omeprazole-Domperidone combination is well tolerated and can be safely used in patients with T2DM and APD receiving OHAs.

